SCOTTSDALE, Ariz., April 6, 2006 (PRIMEZONE) -- Motion DNA Corporation (Pink Sheets:MTDX) today announced that it is commencing to market its new product aimed at helping to meet the demands of the nation's 20,000 Podiatrists. "BioGait 3D," which measures the rotational and angular movements of the foot in 3-D, while either walking or running, is expected to have immediate and universal acceptance in the multi-billion dollar medical market, specifically dealing with problems of the feet, ankle, and lower leg.
According to the American Podiatric Medical Association, untreated foot and ankle problems also may be a significant source of chronic lower back pain for millions of Americans. Findings of this groundbreaking study have demonstrated that the use of a common treatment for correcting such problems have lead to a cure for many sufferers of this debilitating condition.
The legs and lower back operate as one fluid unit -- unimpeded, normal walking motion exerts minimal, if no, strain on the lower back. According to this two-year study, foot and ankle problems restrict or alter normal walking motion, causing a repetitive strain on the lower back. If ignored, this strain, over time, leads to severe lower back muscle damage and resulting pain.
According to Howard J. Dananberg, foremost podiatrist, "This study identifies the nature of a person's walk as a source of chronic lower back pain. It makes perfect sense to focus treatment at the source of the injury. We are hopeful that we can now effectively treat and finally cure the pain of literally millions of people."
Zig Ziegler, founder and CEO of Motion DNA Corporation: "BioGait 3D is our first product specifically targeted at the podiatric medical field, which deals with back, knee, ankle, foot, and lower leg injuries."
With millions of everyday people suffering from chronic problems of the feet and the lower leg including stress fractures, ankle and Achilles tendon pain, and even bunions, Motion DNA expects its unparalleled innovation "BioGait 3D Analysis" to become the state-of-the-art methodology for podiatrists to measure the movements of the foot and the stresses placed on it, and the prediction of most effective courses of medical action to be taken.
"We are constantly putting people in shoes to correct pronation and supination and other postural positions of the foot," added Ziegler. "I recently received two new pairs of orthotics from a local company and found that it temporarily reduced my own back pain but because the orthotics didn't address my underlying physical limitations, the pain came back quickly. BioGait 3D will help podiatrists fix the true problems as we measure the motions of the foot which contributes to our posture."
For complete details and a reservation application, podiatrists are welcomed to visit the Motion DNA website (www.MotionDNACorp.com) to receive a discount on one of the first 100 BioGait systems to be sold. Units are expected to be delivered this month. Company officials believe this is a luxury product at an affordable price. Motion DNA has already received request from podiatrists requesting this type of product which led to the company's development of BioGait-3D.
About Motion DNA Corporation
Based in Scottsdale, Ariz., Motion DNA has developed state-of-art products and services that incorporate advanced 3-D motion-capture technology, which provides diagnostic testing for individual athletes, medical professionals and sports organizations. These types of analyses are designed to identify physical limitations related to strength, mobility, coordination and biomechanics.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
The Motion DNA Corporation logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=2484